Study of Tolerance to Oral Peanut

Efficacy and Safety of High-dose Peanut Oral Immunotherapy With Factors Predicting Outcome

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01259804

Acronym

STOP

Enrollment

Registered

2010-12-14

Start date

2008-01-31

Completion date

2012-01-31

Last updated

2015-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peanut Allergy

Keywords

peanut, food allergy, anaphylaxis, immunotherapy

Brief summary

Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy

Detailed description

Background Peanut allergy is severe and rarely resolves. Objective To test the efficacy and safety of a new oral immunotherapy protocol for peanut allergy. Method 22 peanut-allergic children will undergo oral challenge. Oral immunotherapy will be administered by gradual updosing with 2-weekly increments (8-38w) to 800mg protein (5 peanuts/day) followed by 30-weeks maintenance. Oral challenge will be repeated after 6 and 30 weeks maintenance.

Interventions

DIETARY_SUPPLEMENTPeanut oral immunotherapy

Daily doses of peanut flour

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

7 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Peanut allergy defined by oral challenge

Exclusion criteria

* Major immunodeficiency

Design outcomes

Primary

Measure	Time frame
Pass/fail peanut challenge	six months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 29, 2026